Parallax Volatility Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Parallax Volatility Advisers’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,001	Closed	-$53K	–	3533
2018 Q1	$53K	Sell	1,001 -1,542	-61%	-$89.7K	﹤0.01%	1535
2017 Q4	$136K	Buy	2,543 +2,445	+2,495%	+$136K	﹤0.01%	2585
2017 Q3	$6K	Buy	+98	New	+$5.93K	﹤0.01%	1841
2016 Q3	–	Sell	-44,813	Closed	-$1.74M	–	4136
2016 Q2	$1.74M	Buy	44,813 +16,721	+60%	+$696K	﹤0.01%	982
2016 Q1	$1.14M	Buy	+28,092	New	+$1.78M	﹤0.01%	1136

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Parallax Volatility Advisers's EGRX Position: Q2 2018 in Review

Parallax Volatility Advisers sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2018, closing a stake of 1,001 shares — an estimated $53K sold.

Parallax Volatility Advisers first reported a position in EGRX in Q1 2016 and held it in 5 quarters. The position peaked at $1.74M in Q2 2016. 183 funds tracked by Wall St. Rank hold EGRX as of Q2 2018.

Parallax Volatility Advisers reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Parallax Volatility Advisers sold 1,001 Eagle Pharmaceuticals, Inc. shares in Q2 2018, an estimated $53K.
Parallax Volatility Advisers first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 5 quarters.
Parallax Volatility Advisers's Eagle Pharmaceuticals, Inc. position peaked at $1.74M in Q2 2016.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2018.

Based on Parallax Volatility Advisers's 13F filing for Q2 2018, filed 14 Aug 2018.